Effect of bendrofluazide on the renin-angiotensin-aldosterone system and prostaglandins in captopril-resistant hypertensive patients.
In a double-blind cross-over trial 15 captopril (daily dose 600 mg) treated patients, received in addition to the converting-enzyme inhibitor, placebo or bendrofluazide (7.5 mg). Bendrofluazide lowered blood pressure, while body weight decreased slightly. During captopril-bendrofluazide treatment, the plasma renin-angiotensin-aldosterone system was stimulated, while no effect on the urinary excretion of prostaglandin E2 and F2 alpha was found.
D001539:Bendroflumethiazide / Q000008:administration & dosage / Q000494:pharmacology*; D002216:Captopril / Q000008:administration & dosage / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D015237:Dinoprost; D015232:Dinoprostone; D004311:Double-Blind Method; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011392:Proline / Q000031:analogs & derivatives*; D011458:Prostaglandins E / Q000652:urine; D011460:Prostaglandins F / Q000652:urine; D011897:Random Allocation; D012084:Renin-Angiotensin System / Q000187:drug effects*
D011458:Prostaglandins E; D011460:Prostaglandins F; D001539:Bendroflumethiazide; D011392:Proline; D002216:Captopril; D015237:Dinoprost; D015232:Dinoprostone